Table 3 Comparison of characteristics between CCUS and MDS patients
Variable | CCUS (n = 16) | MN (n = 35) | P |
|---|---|---|---|
Age (y) (Median, range) | 63 (33–78) | 68 (13–87) | 0.058 |
Gender (Male/Female) | 10/6 | 22/13 | < 0.001* |
WBC (× 109/L) (Mean, range) | 3.82 (1.2–8.86) | 2.87 (0.6–7.59) | 0.151 |
Hb (g/L) (Mean, range) | 77 (40–113) | 68 (32–144) | 0.161 |
PLT (× 109/L) (Mean, range) | 87.63 (14–380) | 108.69 (4–760) | 0.666 |
Cytogenetic abnormalities (%) | 21.4% (3/14) | 41.4% (12/29) | < 0.001* |
Mutation rate (%) | 100 (16/16) | 77.1% (27/35) | < 0.001* |
VAF (%) | 38.00 (5.75–94.60) | 45.57 (7.46–91.91) | 0.264 |
Mutations (≥ 2, %) | 43.75% (7/16) | 54.3% (19/35) | < 0.001* |
Adverse mutation (%) | 75% (12/16) | 85.2% (23/27) | 0.043* |
TET2 | 43.75% (7/16) | 17.1% (6/35) | < 0.001* |
ASXL1 | 25% (4/16) | 28.6% (10/35) | < 0.001* |
U2AF1 | 25% (4/16) | 25.7% (9/35) | < 0.001* |
BCOR | 25% (4/16) | 5.7% (2/35) | < 0.001* |
DNMT3A | 6.25% (1/16) | 11.4% (4/35) | < 0.001* |
SF3B1 | 6.25% (1/16) | 11.4% (4/35) | < 0.001* |
TP53 | 6.25% (1/16) | 14.3% (5/35) | < 0.001* |
RUNX1 | 0 (0.0%) | 20% (7/35) | < 0.001* |
STAG2 | 0 (0.0%) | 17.1% (6/35) | < 0.001* |
EZH2 | 0 (0.0%) | 11.4% (4/35) | < 0.001* |
Cardio-cerebrovascular embolism events | 25% (4/16) | 20% (7/35) | < 0.001* |